ePT--the Electronic Newsletter of Pharmaceutical Technology, Sep 13, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
ePT--the Electronic Newsletter of Pharmaceutical Technology, Sep 13, 2012
News
Pfizer Settles Patent Litigation with Mylan
By Jennifer Markarian
Pfizer and Mylan have agreed on terms by which Mylan may launch its generic version of Pfizer's Detrol LA (tolterodine tartrate) extended-release capsules, pending final approval by FDA.
Eli Lilly Receives FDA Warning Letter
By Stephanie Sutton
Eli Lilly has received an FDA Warning Letter because of a "misleading" image of a multicolored brain that appeared on the company's website for the diagnostic PET tracer, Amyvid.
CDER to Expand Office of Generic Drugs
By Susan Haigney
As a result of the passage of the Generic Drug User Fee Amendments Act, Janet Woodcock, director of the Center for Drug Evaluation and Research, announced her plan to reorganize the Office of Generic Drugs (OGD) into a super office that would include subordinate offices. The new super office would report directly to Director Woodcock, with Greg Geba continuing his role as OGD director.
Despite Setbacks, PhRMA Awards Encourage Research into and Fight against Alzheimer's
By Angie Drakulich
Delaying the onset of Alzheimer's disease by just five years could reduce the cost for care of Alzheimer's patients by $447 billion a year by 2050, according to a new PhRMA report.
Just Announced: PhRMA's Research and Hope Award Recipients
By Angie Drakulich
John Castellani, President of PhRMA, talks to PharmTech about its 2012 Research and Hope Award recipients.
Week of September 10, 2012: Cambridge Major Laboratories Expands API Manufacturing Facility; Spectrum Completes Acquisition of Allos Therapeutics; and More
Cambridge Major Laboratories Expands API Manufacturing Facility; Spectrum Completes Acquisition of Allos Therapeutics; and More.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here